Valerio Therapeutics (XPAR:ALVIO) Debt-to-Equity : 0.61 (As of Dec. 2023)

View and export this data going back to 2005. Start your Free Trial

What is Valerio Therapeutics Debt-to-Equity?

Valerio Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €1.78 Mil. Valerio Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €7.22 Mil. Valerio Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was €14.81 Mil. Valerio Therapeutics's debt to equity for the quarter that ended in Dec. 2023 was 0.61.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Valerio Therapeutics's Debt-to-Equity or its related term are showing as below:

XPAR:ALVIO' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.18 Max: 0.61
Current: 0.61

During the past 13 years, the highest Debt-to-Equity Ratio of Valerio Therapeutics was 0.61. The lowest was 0.00. And the median was 0.18.

XPAR:ALVIO's Debt-to-Equity is ranked worse than
78.35% of 1081 companies
in the Biotechnology industry
Industry Median: 0.15 vs XPAR:ALVIO: 0.61

Valerio Therapeutics Debt-to-Equity Historical Data

The historical data trend for Valerio Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Valerio Therapeutics Debt-to-Equity Chart

Valerio Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.50

0.22

0.30

0.45

0.61

Valerio Therapeutics Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.30	0.57	0.45	0.41	0.61

Competitive Comparison of Valerio Therapeutics's Debt-to-Equity

For the Biotechnology subindustry, Valerio Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Valerio Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Valerio Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Valerio Therapeutics's Debt-to-Equity falls into.

Valerio Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Valerio Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.779	+	7.219)	/	14.805
	=	0.61

Valerio Therapeutics's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.779	+	7.219)	/	14.805
	=	0.61

Valerio Therapeutics (XPAR:ALVIO) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Valerio Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Valerio Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Valerio Therapeutics (XPAR:ALVIO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Valerio Therapeutics (XPAR:ALVIO) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

C4X:Germany

Address

49 Boulevard du General, Martial Valin, Paris, FRA, 75015

Website

https://www.valeriotx.com

Valerio Therapeutics is a clinical-stage biotechnology company designing and developing novel oncology drugs targeting tumor DNA repair functions. Its therapeutic strategy focuses on fighting tumor resistance to treatments, which poses ever-greater therapeutic challenges, especially in aggressive or rare cancers. its approach is based upon unique mechanisms of action on DNA Damage Response. The company focuses on bringing first-in-class and disruptive compounds from preclinical research to proof-of-concept in man in cancer indications with high unmet needs.

Valerio Therapeutics (XPAR:ALVIO) Headlines

No Headlines